-
Light-Controlled RNA Release for Regulated Gene Therapy
2026-09-02
This study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic protein production at the level of mRNA translation. By combining reversible light responsiveness with AAV- and cell-based delivery, the authors demonstrate regulated gene therapy concepts for obesity and retinal neovascular disease models.
-
Ranolazine: Mechanism and Research Workflows
2026-09-01
Ranolazine is an anti-ischemic agent that inhibits the cardiac late sodium current and limits sodium-dependent calcium overload. Its documented metabolic actions include glucose oxidation enhancement and inhibition of fatty acid oxidation, while the A8510 research material is supplied for controlled laboratory studies rather than diagnosis or treatment.
-
RapaLink-1 for mTORC1 Inhibition Workflows
2026-09-01
RapaLink-1 is a third-generation mTOR inhibitor for resistance-aware oncology studies and carefully controlled mTORC1 inhibition experiments. This guide translates its bivalent mechanism into glioma, pathway, cell-cycle, and exploratory embryonic dormancy workflows while separating established evidence from testable applications.
-
Protein A/G Magnetic Co-IP/IP Kit for Co-IP
2026-08-31
Translate protein-interaction hypotheses into cleaner pull-downs, reciprocal co-IPs, and MS-ready samples with magnetic separation. The workflow is especially useful for testing pathway relationships such as RNF8–DAPK1 in ischemic neuronal injury while preserving practical options for antibody purification.
-
Isorhamnetin: Reliable Cell Assay Workflows
2026-08-31
Learn how Isorhamnetin (SKU N1358) can support reproducible cell viability, proliferation, apoptosis, and oxidative stress experiments. This scenario-driven guide connects formulation data with published PI3K/Akt findings and practical controls for dose selection, interpretation, and supplier evaluation.
-
Palbociclib (PD0332991): CDK4/6 Research Guide
2026-08-30
Palbociclib (PD0332991) is a selective CDK4/6 inhibitor that suppresses Rb phosphorylation and produces G0/G1 cell-cycle arrest in susceptible cancer models. This guide connects the A8335 research reagent to breast cancer research, renal cell carcinoma studies, assay design, and evidence-based limitations.
-
Dual-Action Kinase Inhibitors and p38α Dephosphorylation
2026-08-29
The reference study shows that some kinase inhibitors can do more than block catalytic activity: they can reshape the p38α activation loop to make its phosphothreonine more accessible to the phosphatase WIP1. This conformational mechanism suggests a route toward kinase inhibitors whose potency and selectivity derive from coordinated kinase inhibition and accelerated dephosphorylation.
-
Ciprofloxacin, Zinc, and RSL3-Induced Ferroptosis
2026-08-28
This study identifies a context-dependent role for ciprofloxacin in ferroptosis: unlike its previously reported protection against erastin, ciprofloxacin enhances RSL3-induced ferroptosis in cancer cells. The proposed mechanism connects topoisomerase 2β inhibition and mitochondrial DNA stress to the STING1–CAV2 pathway, mitochondrial Zn2+ accumulation, and reactive oxygen species amplification.
-
Methoprene as a Probe of Juvenile Hormone Control
2026-08-28
A mechanistic and translational guide to using (S)-(+)-Methoprene as a juvenile hormone analog, connecting receptor-level perturbation with miRNA–mRNA control of biosynthesis, insect development, reproduction, and comparative endocrine research.
-
Nitazoxanide Reverses Pulmonary Vascular Remodeling
2026-08-27
A February 2026 study identifies IMPA1 as a direct molecular target of nitazoxanide and connects IMPA1-RAGE signaling with PI3K/Akt/mTOR activation, glycolytic reprogramming, and pulmonary artery smooth muscle cell behavior. Across two experimental pulmonary hypertension models, the findings position nitazoxanide as a preclinical candidate for addressing vascular remodeling rather than only pulmonary vasoconstriction.
-
Glabridin-Gold(I) Complex Enhances Antitumor Immunity
2026-08-27
The reference study develops glabridin-gold(I) complex 6d as an immunomodulatory agent that simultaneously targets thioredoxin reductase and MAPK-associated immunosuppression. Its findings connect tumor-cell immunogenicity with changes in dendritic cells, suppressive myeloid populations, regulatory T cells, PD-L1, and granzyme B, while suggesting mitochondrial readouts as useful complementary endpoints for follow-up studies.
-
HDAC Inhibition Reverses EBV-Driven NPC Plasticity
2026-08-26
This study identifies an epigenetic mechanism by which EBV latent membrane protein 1 drives dedifferentiation and stem-like plasticity in nasopharyngeal carcinoma. It further shows that HDAC inhibition restores CEBPA expression and reverses this phenotype in xenograft models, providing a mechanistic rationale for differentiation-oriented cancer therapy in solid tumors.
-
In Vitro Embryonic Dormancy Through mTOR Inhibition
2026-08-26
Iyer and colleagues provide reversible in vitro protocols for inducing a diapause-like dormant state in mouse blastocysts, human blastoids, and mouse or human pluripotent stem cells through pharmacological mTOR inhibition. The work replaces invasive surgery-based models with scalable culture workflows for studying embryonic dormancy, developmental competence, and the molecular control of early development.
-
TaqI Restriction Endonuclease Protocol
2026-08-25
TaqI Restriction Endonuclease provides rapid, sequence-specific cleavage of plasmid DNA, PCR products, and genomic DNA at the TCG A recognition site, supporting cloning and DNA analysis workflows that require sticky ends. It is intended for scientific research use only and should not be used for diagnostic or medical applications.
-
Concanamycin A: From Acidification to Translation
2026-08-25
A translational framework for using Concanamycin A to connect V-ATPase-dependent acidification with trafficking, apoptosis, invasion, and experimentally actionable cancer biology decisions.